Lumefantrine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 17, 2026🚩 Report this page

Lumefantrine

Active ingredient

GB MHRA

Drug class: -
Availability: See label
Markets covered: 1
Products on record: 1

Overview

Lumefantrine is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	April 17, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised April 17, 2026[1]

Riamet is indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria in adults, children and infants of 5 kg and above. Consideration should be given to official guidance regarding the appropriate use of antimalarial agents.

How to take

Drug interactions

Known interactions involving Lumefantrine. Select one for details. This list is informational and not a complete interaction checker.

Abarelix Abiraterone Adenosine Alfuzosin Amiodarone Amisulpride Amitriptyline Amoxapine Anagrelide Apomorphine Arsenic Trioxide Asenapine Astemizole Azithromycin Bedaquiline Bepridil Bicalutamide Bosutinib Buprenorphine Cabozantinib Chloroquine Chlorpromazine Ciprofloxacin Cisapride Citalopram Clofazimine Clomipramine Clozapine Crizotinib Dasatinib Daunorubicin Degarelix Desipramine Deutetrabenazine Disopyramide Dofetilide Dolasetron Doxepin Doxorubicin Dronedarone Droperidol Encorafenib Entrectinib Epirubicin Eribulin Escitalopram Ezogabine Fingolimod Flecainide Fluconazole Fluoxetine Fluphenazine Flutamide Foscarnet Fostemsavir Gatifloxacin Gemifloxacin Gilteritinib Glasdegib Goserelin Granisetron Grepafloxacin Halofantrine Haloperidol Halothane Histrelin Hydroxychloroquine Hydroxyzine Ibutilide Idarubicin Iloperidone Imipramine Inotuzumab Ozogamicin Isoproterenol Ivabradine Ivosidenib Lapatinib Lefamulin Lenvatinib Leuprolide Levofloxacin Lisdexamfetamine Lithium Carbonate Lofexidine Lomefloxacin Macimorelin Maprotiline Mefloquine Mesoridazine Metaproterenol Methadone Methotrimeprazine Midostaurin Mirtazapine Moxifloxacin Nilotinib Nilutamide Norfloxacin Nortriptyline Ofloxacin Oliceridine Ondansetron Osilodrostat Osimertinib Oxaliplatin Oxytocin Ozanimod Paliperidone Palonosetron Panobinostat Papaverine Pasireotide Pazopanib Pentamidine Perflutren Perphenazine Pimavanserin Pimozide Pitolisant Primaquine Probucol Procainamide Prochlorperazine Promazine Promethazine Propafenone Propoxyphene Protriptyline Quetiapine Quinidine Quinine Ranolazine Ribociclib Rilpivirine Risperidone Ritodrine Romidepsin Rucaparib Selpercatinib Sertraline Sevoflurane Siponimod Solifenacin Sorafenib Sotalol Sparfloxacin Sunitinib Tacrolimus Tamoxifen Telavancin Telithromycin Terbutaline Terfenadine Tetrabenazine Thioridazine Tizanidine Toremifene Tramadol Trazodone Triclabendazole Trifluoperazine Triflupromazine Trimeprazine Trimipramine Triptorelin Valbenazine Vandetanib Vardenafil Vemurafenib Venlafaxine Voriconazole Ziprasidone Albuterol Arformoterol Aripiprazole Atomoxetine Bisacodyl Carvedilol Castor Oil Cevimeline Codeine Darifenacin Dextromethorphan Donepezil Duloxetine Famotidine Fluvoxamine Formoterol Galantamine Glycerin Indacaterol Isoetharine Labetalol Lactitol Lactulose Loperamide Loratadine Magnesium Citrate Magnesium Hydroxide Metoprolol Mexiletine Mineral Oil Morphine Nebivolol Olanzapine Olodaterol Oxycodone Paroxetine Phenolphthalein Pindolol Pirbuterol Pirfenidone Polyethylene Glycol 3350 Propofol Propranolol Rifapentine Rivastigmine Ropivacaine Salmeterol Tacrine Thalidomide Timolol Metronidazole Sulfamethoxazole Tolterodine

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL238600024 · revised April 17, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised April 17, 2026[1]

The safety of Riamet has been evaluated in 20 clinical trials with more than 3500 patients. A total of 1810 adults and adolescents above 12 years of age as well as 1788 infants and children of 12 years of age and below have received Riamet in clinical trials.
Adverse reactions reported from clinical studies and post-marketing experience are listed below according to system organ class. Adverse reactions are ranked under headings of frequency using the MedDRA frequency convention: Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) Not known (cannot be estimated from available data).
2 %) Gait disturbance Common -- *: These adverse reactions were reported during post-marketing experience. Because these spontaneously reported events are from a population of uncertain size, it is difficult to estimate their frequency.
#: Has been reported up to a few weeks after treatment has been stopped. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised April 17, 2026[1]

6). Riamet has not been evaluated for the treatment of severe malaria, including cases of cerebral malaria or other severe manifestations such as pulmonary oedema or renal failure. 5) unless there is no other treatment option. If a patient deteriorates whilst taking Riamet, alternative treatment for malaria should be started without delay.
In such cases, monitoring of the ECG is recommended and steps should be taken to correct any electrolyte disturbances. The long elimination half-life of lumefantrine must be taken into account when administering quinine in patients previously treated with Riamet.
5). 5). In patients previously treated with halofantrine, Riamet should not be administered earlier than one month after the last halofantrine dose. Riamet is not indicated and has not been evaluated for prophylaxis of malaria. 5). g. 1).
Caution is recommended when combining Riamet with drugs exhibiting variable patterns of inhibition, moderate induction or competition for CYP3A4 as the therapeutic effects of some drugs could be altered. 2). Caution is recommended when combining Riamet with hormonal contraceptives.
Riamet may reduce the effectiveness of hormonal contraceptives. 5). Patients who remain averse to food during treatment should be closely monitored as the risk of recrudescence may be greater. Renal impairment No specific studies have been carried out in this group of patients.
There is no significant renal excretion of lumefantrine, artemether and dihydroartemisinin in studies conducted in healthy volunteers and clinical experience is limited. No dose adjustment for the use of Riamet in patients with renal impairment is recommended.
Caution is advised when administering Riamet to patients with severe renal impairment. In these patients, ECG and blood potassium monitoring is advised. Hepatic impairment No specific studies have been carried out in this group of patients.
In patients with severe hepatic impairment, a clinically relevant increase of exposure to artemether and lumefantrine and/or their metabolites cannot be ruled out. 2). In these patients, ECG and blood potassium monitoring is advised.
No dose adjustment is recommended for patients with mild to moderate hepatic impairment. New infections Data for a limited number of patients in a malaria endemic area show that new infections can be treated with a second course of Riamet.
In the absence of carcinogenicity study data, and due to lack of clinical experience, more than two courses of Riamet cannot be recommended. e. ”

This is not medical advice. Consult a qualified healthcare professional.